BOSTON–(COMMERCIAL THREAD) –908 devices (NASDAQ: MASS), a pioneer of portable and desktop mass specification devices specifically designed for chemical and biomolecular analysis, today announced two data analysis partnerships to integrate with the REBEL â¢, the first in-line fresh and used cell media analyzer for bioprocess laboratories. With the integration of a leading data mining tool SIMCA by SartoriusÂ® and Securecell Lucullus Process Information Management System (PIMS), users can seamlessly transform REBEL data into deeper actionable insights to drive operational excellence.
âWe strive to provide our customers with the most actionable bioanalytical information possible as simply as possible. By integrating SIMCA and Lucullus with our REBEL platform, we provide connectivity to process and data analysis tools to help our REBEL customers make informed decisions and be more efficient in their process development efforts, â said Steve Davenport, vice president of commercial sales for 908. Devices. âAs our process development clients focus on leveraging larger analytical datasets, in part due to the wealth of data now delivered with REBEL, we will continue to focus on helping them get the tools and the methods needed to extract data and collect information. ”
908 Devices has partnered with Sartorius to enable customers to take advantage of the multivariate modeling used in SIMCA, which identifies hidden trends and patterns not visible by univariate data analysis methods. Here’s how REBEL customers can make data-driven decisions faster with SIMCA:
Transparent data flow from REBEL to SIMCA to improve process development analysis
Improved data visualization, via interactive plots and direct exploratory analyzes, providing easy access to visualization and interpretation of data models, accelerating the identification of nutrient trends
Improved Quality-by-Design (QbD) approaches
908 Devices has partnered with Securecell to provide REBEL users with comprehensive Critical Process Parameter (CPP) monitoring and data management, from raw material to final product. Here’s how REBEL customers can perform more sophisticated data collection when monitoring cell culture media metrics with Lucullus:
Streamlined user interface and automated visualization of trends in fresh or used cell culture media for rapid selection and optimization
Ability to store all analytical results of medium quality control tests in one place
Simplified correlation of nutrients and metabolites through streamlined data management, integrating with other data sources in the bioprocess environment
Big Data approaches, such as the one discussed in our Blog, can speed up drug pipelines to ensure that once a biologic is put into production, the process has already been designed to provide high yields and batch-to-batch consistency. Such data mining approaches are made possible through the integration of these two well known and widely used software tools. REBEL users can now visualize data and spot trends quickly and more easily. The REBEL itself disrupts bioprocess development with rapid online analysis of cell culture media, allowing process development laboratories to analyze cell media in real time. The answers are provided – not just the data – and users can use the device where they need it, right next to their bioreactor rather than relying on the remote central lab or third-party service providers.
To learn more about the REBEL and 908 devices, please visit: https://908devices.com/.
About 908 devices
908 Devices (NASDAQ: MASS) democratizes laboratory mass spectrometry with its simple portable and desktop devices, addressing life-critical applications. The company’s devices are used at the point of need to interrogate unknown and invisible materials and provide rapid, actionable responses to directly address some of the most critical issues in life science research, bioprocesses, pharma / biopharma , forensics and adjacent markets. The company is headquartered in the heart of Boston, where it designs and manufactures innovative products that combine the power of mass spectrometry, microfluidic separations, software automation and machine learning.
This press release contains “forward-looking statements”, including statements relating to the Company’s new partnership capabilities and the expected impact on drug pipelines. Forward-looking statements involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from results expressed or implied by any forward-looking statement, including the risks described under âRisk Factorsâ and elsewhere in documents filed by the Company with the Securities and Exchange Commission which are available on the SEC’s website at www.sec.gov. Additional information will be available in our annual and quarterly reports and in other documents that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and undertakes no obligation, to update or revise any forward-looking statements made in this press release to reflect changes since the date of this press release, except as required by law requires it.